Medical technology company GE HealthCare (NASDAQ: GEHC) announced on Wednesday that it has introduced a new AI-enabled application orchestration feature, integrated into its True PACS and Centricity PACS systems, through a collaboration with Blackford.
This new offering aims to assist radiologists in managing increased workloads and exam complexities, enabling quicker diagnoses and treatments. The platform provides access to a catalog of third-party AI applications, covering areas from mammography to lung scans.
As clinician burnout rises - 49% of radiologists cited excessive bureaucratic tasks as a key issue in an RSNA survey - GE HealthCare's AI solutions focus on improving workflow efficiency. This aligns with the company's precision care framework, which integrates smart devices, targeted therapies, and digital solutions to enhance care quality.
GE HealthCare currently leads the U.S. Food and Drug Administration's (FDA) list of AI-enabled medical devices, with 80 clearances to date. The AI orchestration feature simplifies the integration of AI into clinical workflows, offering a streamlined process for healthcare providers to access and implement imaging AI solutions.
The new technology will be showcased at the Radiological Society of North America's annual meeting in Chicago from 1-4 December 2023.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition